SCHEMBL25431544

SCHEMBL25431544

CCOC(=O)Cc1nn(C(C)C)c2cc(Br)ccc2c1=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 2/20 0.59
▸ JAK2 O60674 1/20 0.45
▸ PAK4 O96013 1/20 0.45
▸ NTRK1 P04629 1/20 0.45
▸ LCK P06239 1/20 0.45
▸ FYN P06241 1/20 0.45
▸ CSF1R P07333 1/20 0.45
▸ RET P07949 1/20 0.45
▸ MET P08581 1/20 0.45
▸ PDGFRB P09619 1/20 0.45
▸ PIM1 P11309 1/20 0.45
▸ FGFR1 P11362 1/20 0.45
▸ PRKACA P17612 1/20 0.45
▸ GRK5 P34947 1/20 0.45
▸ MAP2K2 P36507 1/20 0.45
▸ FLT3 P36888 1/20 0.45
▸ MAPK8 P45983 1/20 0.45
▸ CDK8 P49336 1/20 0.45
▸ GSK3A P49840 1/20 0.45
▸ GSK3B P49841 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25356354 0.89 NLRP3 (0.64) NLRP3JAK2PAK4NTRK1LCK
SCHEMBL29492185 0.85 NLRP3 (0.64) NLRP3TYRO3MEN1KMT2APOLB
SCHEMBL29492205 0.84 NLRP3 (0.43) NLRP3SMN1; SMN2RECQLALDH1A1MEN1
SCHEMBL25356861 0.79 NLRP3 (0.57) NLRP3MAPK8TYRO3LMNAPOLB
SCHEMBL29494685 0.76 NLRP3 (0.52) NLRP3MAPK8TYRO3LMNAPOLB
SCHEMBL29492036 0.74 NLRP3 (1.00) NLRP3NTRK1
SCHEMBL705011 0.74 NLRP3 (0.47) NLRP3RETTYRO3POLB
SCHEMBL25356370 0.73 NLRP3 (0.53) NLRP3MAPK8GSK3BTYRO3DYRK1A
SCHEMBL29591752 0.73 CFD (0.46) NLRP3JAK2PAK4NTRK1LCK
SCHEMBL29852929 0.73 CFD (0.46) NLRP3JAK2PAK4NTRK1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217346-B1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2025-07-02 — — EP disclosed
US-20230391756-A1 NEW COMPOUND JANSSEN PHARMACEUTICA NV (BE) 2023-12-07 — — US disclosed
EP-4217346-A1 NEW COMPOUNDS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
WO-2022063876-A1 NEW COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391756-A1 NEW COMPOUND NLRP3, NLRP1, IL1R1 NLRP3 1/4885JAK2 3688/4885PAK4 4402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback